909089-13-0 Usage
Description
SKL2001 is an activator of Wnt/β-catenin signaling, which plays a crucial role in various cellular processes, including cell proliferation, differentiation, and migration. It has the ability to increase β-catenin responsive transcription, disrupt the interaction between Axin and β-catenin, and enhance osteoblastogenesis.
Uses
Used in Pharmaceutical Industry:
SKL2001 is used as a therapeutic agent for promoting osteoblastogenesis and treating bone-related disorders. It increases alkaline phosphatase activity and mineralization in multipotent mesenchymal ST2 cells, indicating its potential in enhancing bone formation and regeneration.
Used in Cancer Research:
SKL2001 is used as a research tool for studying the role of Wnt/β-catenin signaling in cancer progression. It has been shown to reduce spheroid growth and inhibit proliferation of certain cancer cells, such as HCT116 and HT-29, by inducing cell cycle arrest at the G0/G1 phase and increasing E-cadherin and β-catenin protein levels.
Used in Cell Biology Research:
SKL2001 is used as a research tool for investigating the molecular mechanisms underlying the regulation of Wnt/β-catenin signaling and its impact on various cellular processes, such as cell proliferation, differentiation, and migration.
Check Digit Verification of cas no
The CAS Registry Mumber 909089-13-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,9,0,8 and 9 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 909089-13:
(8*9)+(7*0)+(6*9)+(5*0)+(4*8)+(3*9)+(2*1)+(1*3)=190
190 % 10 = 0
So 909089-13-0 is a valid CAS Registry Number.
909089-13-0Relevant articles and documents
PHARMACEUTICAL COMPOSITION FOR PREVENTINTION AND TREATMENT OF RESTENOSIS COMPRISING ISOXAZOLE DERIVATIVES
-
Page/Page column 19, (2009/03/07)
There is provided a pharmaceutical composition for prevention and treatment of restenosis comprising isoxazole derivatives. The pharmaceutical composition includes a therapeutic effective amount of isoxazole derivatives represented by Formula 1 or pharmaceutically available salts thereof. The pharmaceutical composition may be useful to prevent and treat vascular restenosis since the pharmaceutical composition shows an anti-restenosis activity and accelerates the re-endothelization.
ISOXAZOLE DERIVATIVES AND USE THEREOF
-
Page/Page column 35; 36, (2010/11/28)
Disclosed herein are isoxazole derivaties and uses thereof. Serving as agonists of Wnt, the isoxazole derivatives activate Wnt/β-catenin signaling and thus can be used in the treatment and prevention of diseases related to the signal transduction. Also, pharmaceutically acceptable salts of the isoxazole derivatives are disclosed.
